Thanks to the good antitumor efficacy of NTRK inhibitors, both in adults and children, there is a great need for individualized prognosis of pediatric GIST with genetic studies, including NTRK genes fusion status study, e.g., using hybrid capture DNA-based targeted panels (UCSF500 Cancer Gene Panel and OncoPanel) that include probes for exons and select introns of NTRK1, NTRK2, and NTRK3, as well as ETV6 exonic and intronic probe [17,19,20]. Here, NTRK1 is linked to gastrointestinal stromal tumor.